Madrigal Pharmaceuticals Inc (MDGL) reports robust Q3 sales driven by Rezdiffra demand, while navigating increased SG&A ...

Novo's Rival Drug Shows Promise, But Madrigal's First-Mover Advantage Keeps Investors Hooked--What's Next for This Rising ...

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $236 from $194 and keeps a Neutral rating on the shares. Madrigal’s Q3 earnings “blowout” print ...

Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval. Read why I maintain my buy rating ...

With the FDA approval of the first specific drug for Metabolic Associated Steatohepatitis (MASH) in March this year, Madrigal’s Rezdiffra is a pioneer in a market set for rapid change. | With the FDA ...

Q3 2024 Earnings Call Transcript October 31, 2024 Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is ...

Nearly a dozen candidates are up for City Council seats representing northeast, central and south central Oxnard.

Jefferies analyst Akash Tewari maintained a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target ...

An unrenovated unit in the Bloomingdale’s building sold for $1.02 million, highlighting depreciation in Chicago’s downtown ...

Regeneron shares continued to decline on growing concerns about Eylea’s future. Elsewhere, new details emerged about Lundbeck ...

Explaining that social media “is getting hammered by disinformation,” Madrigal and the video are part of a campaign by CALÓ ...